SAMAD SAM 4

What Happened

• SAMAD SAM, a director of IDEXX Laboratories, received two types of equity awards on 2026-05-12: 525 option shares (derivative) and 234 deferred stock units (derivative). Both awards are reported at $0.00 (grant value reported as acquisition price) and do not represent an immediate purchase or sale of common stock.
• These awards total 759 contingent awards. The options give a right to buy common stock (see footnote F1); the deferred stock units represent contingent rights to receive one share each (see footnote F2).

Key Details

• Transaction date: 2026-05-12; Form 4 filed: 2026-05-14 (filed within the usual two-business-day window).
• Items granted: 525 options (F1) and 234 deferred stock units (F2); both reported at $0.00 acquisition price.
• Vesting: Both awards vest in one installment on the one‑year anniversary of the grant or on the date of the 2027 annual meeting of shareholders, whichever is earlier.
• Deferred stock units: by default payable as common stock as soon as practicable following a director’s resignation (per F2).
• Shares owned after the transaction: not disclosed in this filing.

Context

• These are director compensation grants (award code A), not open‑market purchases or sales; they create potential future ownership if/when vesting and any option exercises occur.
• For retail investors, such grants are routine for board members and do not by themselves signal near‑term buying or selling.